Trial Profile
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BROCADE3
- Sponsors AbbVie; AbbVie Germany
- 14 Mar 2024 This trial has been discontinued in Germany, Austria, and Spain, according to European Clinical Trials Database.
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 04 Feb 2024 The trial has been discontinued in Italy.